GENE ONLINE|News &
Opinion
Blog

Solutions, Challenges, and Opportunities in Pandemic

by GeneOnline
Share To

With “Finding Cures in the Crisis” the theme, BIO Asia-Taiwan 2020 has scheduled two full sessions of presentations over two days focused entirely on strategies to combat the pandemic. These not-to-be-missed discussions will be led by world-leading experts in diagnostics, vaccine development, therapeutics, and public health.

In addition to these two sessions, there are many more forward-looking topics covering the “post-COVID19” challenges and trends on the regulatory, government policy, technology, and the global business and partnering model.

Learn how Taiwan successfully beat the odds, held back the COVID-19 threat, and take a close look at new treatments under development in labs and clinics not just in Asia but around the world.

The first major biomedical conference to be held in Asia since the onset of the pandemic, BIO Asia–Taiwan 2020 will take you to the front line where companies, research institutes, and governments are working tirelessly on this critical mission.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
The U.S. COVID-19 Public Health Emergency Ends in May, but FDA’s EUA Authority Remains
2023-02-01
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
2023-01-03
Novavax Offers Up $125 Million Of Stock For COVID-19 Vaccine Launch
2022-12-20
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top